(OCGN) Ocugen - Ratings and Ratios
Gene Therapy, Vaccines, Biologics, Cell Therapy
OCGN EPS (Earnings per Share)
OCGN Revenue
Description: OCGN Ocugen
Ocugen Inc (NASDAQ:OCGN) is a biopharmaceutical company focused on developing innovative gene and cell therapies, biologics, and vaccines. The companys diverse pipeline includes several promising candidates, such as OCU400, a gene therapy for inherited retinal diseases, and OCU410, a gene therapy for dry age-related macular degeneration. With a strong research and development foundation, Ocugen has established strategic partnerships, including a collaboration with the National Institute of Allergy and Infectious Diseases and a manufacturing partnership with CanSino Biologics Inc.
Key pipeline products are in various stages of clinical trials, including Phase 3 trials for OCU400 and NeoCart, indicating a potential for near-term milestones. The companys vaccine development programs, including OCU500 for COVID-19 and OCU510 for seasonal flu, demonstrate its commitment to addressing pressing public health concerns. With a market capitalization of $283.27M USD, Ocugens financials will be critical in supporting its R&D endeavors. Notable KPIs to monitor include the progress of its clinical trials, cash burn rate, and partnership announcements, which can significantly impact the stocks performance.
From a financial perspective, Ocugens lack of profitability is reflected in its negative P/E ratio, while its forward P/E of 15.22 suggests potential future earnings growth. The companys return on equity (RoE) of -223.00 indicates significant investment in R&D. Investors should closely monitor Ocugens cash reserves, R&D expenses, and potential future revenue streams to gauge its financial health and ability to execute on its pipeline.
As a Trading Analyst, its essential to track Ocugens progress in its clinical trials, particularly the outcome of Phase 3 trials for OCU400 and NeoCart. Additionally, monitoring the companys cash burn rate and potential future financing rounds will be crucial. Key performance indicators (KPIs) to watch include the number of patients enrolled in trials, trial completion rates, and any significant partnership or licensing announcements, which can impact the stocks price.
OCGN Stock Overview
| Market Cap in USD | 334m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2014-12-03 |
OCGN Stock Ratings
| Growth Rating | -13.2% |
| Fundamental | 39.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -0.57% |
| Analyst Rating | 4.50 of 5 |
OCGN Dividends
Currently no dividends paidOCGN Growth Ratios
| Growth Correlation 3m | 19% |
| Growth Correlation 12m | 24% |
| Growth Correlation 5y | -47.7% |
| CAGR 5y | -12.00% |
| CAGR/Max DD 3y | -0.15 |
| CAGR/Mean DD 3y | -0.22 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.15 |
| Beta | 0.837 |
| Volatility | 89.82% |
| Current Volume | 8841.6k |
| Average Volume 20d | 1683.8k |
| Stop Loss | 1.2 (-9.1%) |
| Signal | 3.42 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-56.9m TTM) > 0 and > 6% of Revenue (6% = 285.2k TTM) |
| FCFTA -0.85 (>2.0%) and ΔFCFTA 93.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 313.3% (prev 5.42%; Δ 307.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.97 (>3.0%) and CFO -51.7m > Net Income -56.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (292.0m) change vs 12m ago 13.47% (target <= -2.0% for YES) |
| Gross Margin 87.42% (prev 20.63%; Δ 66.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 10.10% (prev 29.33%; Δ -19.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -28.09 (EBITDA TTM -52.3m / Interest Expense TTM 1.97m) >= 6 (WARN >= 3) |
Altman Z'' -36.24
| (A) 0.28 = (Total Current Assets 32.9m - Total Current Liabilities 18.0m) / Total Assets 53.6m |
| (B) -6.91 = Retained Earnings (Balance) -370.3m / Total Assets 53.6m |
| warn (B) unusual magnitude: -6.91 — check mapping/units |
| (C) -1.18 = EBIT TTM -55.4m / Avg Total Assets 47.1m |
| (D) -7.27 = Book Value of Equity -367.4m / Total Liabilities 50.5m |
| Total Rating: -36.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.05
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -13.51% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 9.74 = -2.50 |
| 5. Debt/Ebitda -0.57 = -2.50 |
| 7. RoE -255.3% = -2.50 |
| 8. Rev. Trend 17.33% = 1.30 |
| 9. EPS Trend 75.03% = 3.75 |
What is the price of OCGN shares?
Over the past week, the price has changed by +26.92%, over one month by +26.92%, over three months by +21.10% and over the past year by +17.86%.
Is Ocugen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OCGN is around 0.99 USD . This means that OCGN is currently overvalued and has a potential downside of -25%.
Is OCGN a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OCGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 392.4% |
| Analysts Target Price | 6.5 | 392.4% |
| ValueRay Target Price | 1.1 | -16.7% |
Last update: 2025-09-15 04:41
OCGN Fundamental Data Overview
CCE Cash And Equivalents = 27.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 15.2207
P/S = 70.2916
P/B = 109.4908
Beta = 4.163
Revenue TTM = 4.75m USD
EBIT TTM = -55.4m USD
EBITDA TTM = -52.3m USD
Long Term Debt = 28.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.71m USD (from shortTermDebt, last quarter)
Debt = 29.7m USD (Calculated: Short Term 1.71m + Long Term 28.0m)
Net Debt = 5.81m USD (from netDebt column, last quarter)
Enterprise Value = 336.9m USD (334.2m + Debt 29.7m - CCE 27.0m)
Interest Coverage Ratio = -28.09 (Ebit TTM -55.4m / Interest Expense TTM 1.97m)
FCF Yield = -13.51% (FCF TTM -45.5m / Enterprise Value 336.9m)
FCF Margin = -957.7% (FCF TTM -45.5m / Revenue TTM 4.75m)
Net Margin = -1198 % (Net Income TTM -56.9m / Revenue TTM 4.75m)
Gross Margin = 87.42% ((Revenue TTM 4.75m - Cost of Revenue TTM 598.0k) / Revenue TTM)
Tobins Q-Ratio = -0.92 (set to none) (Enterprise Value 336.9m / Book Value Of Equity -367.4m)
Interest Expense / Debt = 3.56% (Interest Expense 1.06m / Debt 29.7m)
Taxrate = 21.0% (US default)
NOPAT = -55.4m (EBIT -55.4m, no tax applied on loss)
Current Ratio = 1.83 (Total Current Assets 32.9m / Total Current Liabilities 18.0m)
Debt / Equity = 9.74 (Debt 29.7m / last Quarter total Stockholder Equity 3.05m)
Debt / EBITDA = -0.57 (Net Debt 5.81m / EBITDA -52.3m)
Debt / FCF = -0.65 (Debt 29.7m / FCF TTM -45.5m)
Total Stockholder Equity = 22.3m (last 4 quarters mean)
RoA = -106.2% (set to none)
RoE = -255.3% (Net Income TTM -56.9m / Total Stockholder Equity 22.3m)
RoCE = -110.0% (set to none) (Ebit -55.4m / (Equity 22.3m + L.T.Debt 28.0m))
RoIC = -125.5% (set to none) (NOPAT -55.4m / Invested Capital 44.1m)
WACC = 8.59% (E(334.2m)/V(363.9m) * Re(9.10%)) + (D(29.7m)/V(363.9m) * Rd(3.56%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.75%
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -45.5m)
EPS Correlation: 75.03 | EPS CAGR: 139.2% | SUE: 0.88 | # QB: 1
Revenue Correlation: 17.33 | Revenue CAGR: 154.6% | SUE: 0.80 | # QB: 0
Additional Sources for OCGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle